The correlation of CRP/Alb ratio with low muscle mass in patients with type 2 diabetes mellitus: a cross-sectional research
摘要
Sarcopenia is a prominent age-related condition with low muscle mass, yet its underlying pathogenesis remains unclear. Type 2 diabetes mellitus (T2DM) is a well-recognized risk factor for this disorder. Recent data indicates that low muscle mass or sarcopenia is closely linked to high C-reactive protein-to-albumin (CRP/Alb) ratio in patients with esophageal, gastric and colorectal cancers.
MethodsTherefore, this study aimed to investigate the association between the CRP/Alb ratio and low muscle mass in a T2DM population. This study included 1009 participants (549 males and 460 females) diagnosed with T2DM. Dual energy X-ray absorptiometry was utilized to measure the skeletal muscle index (SMI). Low muscle mass was identified based on the diagnostic criteria established by the Asian Working Group for Sarcopenia (AWGS).
ResultsOur findings revealed that low muscle mass was present in 110 male patients (20.04%) and 62 female patients (13.48%). In univariate logistic regression analysis, the C-reactive protein -to-Albumin ratio (CRP/Alb) was significantly associated with low muscle mass in men with T2DM (Odds Ratio (OR) = 1.084 [95%CI = 1.014 ~ 1.158], p = 0.017). The association remained significant after adjusting for age, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), diastolic blood pressure (DBP) and body mass index (BMI) in the multiple logistic regression model (OR = 1.142 [95%CI = 1.028 ~ 1.269], p = 0.013). No significant association between CRP/Alb ratio and the risk of low muscle mass was observed in the female participants (OR = 0.975 [95%CI = 0.868 ~ 1.095], p = 0.672). In multiple linear regression analyses, SMI was positively associated with Alb, BMI, total cholesterol (TC) and HbA1c in males, but negatively related to associated with age. In females, SMI was positively associated with BMI and smoking duration.
ConclusionThe CRP/Alb ratio was positively related to low muscle mass in men with T2DM.
Clinical trial numberNot applicable.